Cardiovascular risk reduction in HIV positive patients
Int J Atheroscler 2007;2(4):279-283
Cardiovascular risk reduction in
HIV positive patients
Results from short-term medical intervention
Pai Ching Yu, Daniela Calderaro, Danielle Menosi Gualandro, Eneas Martins de Oliveira Lima,
Isabela de Carlos Back Giuliano, Carolina Letícia Zilli Vieira, Bruno Caramelli
Abstract
Objectives: The hypothesis of this study is that the prevention of atherosclerosis in HIV patients can be successfully applied by general practicioners following the “classical” risk factors control ap-proach. Design: A prospective cohort study, including 100 HIV-infected patients referred for sus-pected increased cardiovascular risk. Methods: Based on the Framingham Risk Score (FRS), pa-tients received intervention to achieve the desirable control of risk factors. Non-pharmacological treatment consisted of counselling lifestyle modification. Hypolipemic and/or antihypertensive medi-cation was associated when necessary. Cardiac risk was reassessed 5 months later. Results: 24% of the patients had diabetes, 32% were smokers, and 95% were receiving HAART. The average FRS at the start of the trial was 11.94±8.69. After intervention, there was a significant decrement of total cholesterol (241.03±55.86 x 218.93±52.50 mg/dL, p<0.0001), LDL-cholesterol (140.34±43.29 x 127.57±42.62 mg/dL, p=0.01) and triglycerides (285.82±224.25 x 236.09±138.41 mg/dL, p=0.002). Elevated risk patients (FRS>10%) frequency decreased from 58 to 40% (95% confi-dence interval 0.04 to 0.32, p=0.03). Conclusions: Easy applicable preventive intervention based on lifestyle modifications and pharmacological therapy was able to reduce cardiovascular risk in HIV-infected patients.
Key words: Cardiovascular risk; Atherosclerosis; Dyslipidemia; Prevention; HAART; HIV; Switching
Introduction
Since the introduction of Highly Active Anti-Retroviral Therapy (HAART), the life expectancy of patients with hu-man immunodeficiency virus (HIV) infection has dramatically increased. Living with Acquired Immunodeficiency Syndrome and all related disturbances has become a long-term condi-tion. As life expectancy increases, HIV-infected patients are naturally going to face the chronic degenerative processes that affect the overall population, such as atherosclerotic disease and specific prevention strategies, if necessary, should be established. The prevention of atherosclerotic dis-ease in the HIV-infected population has specific constraints.First of all, beyond the chronic inflammation and in-fection process per se, the treatment, especially protease inhibitors, is associated with a wide ra nge of metabolic alterations1-4..Indeed, disturbances of lipid profile, glucose intolerance, insulin resistance and lipodystrophy have been described in 60-70%5,6 of patients and could contribute to the development of early coronary and cerebrovascular disease7,8. Second, despite the consensual recommen-dation for cardiovascular risk assessment, the effective strategies for the prevention of atherosclerosis addressed to the general population should be tested in patients al-ready dealing for a long time with important constraints
Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.
Correspondence: Bruno Caramelli, Heart Institute, University of São Paulo Medical School, Bloco II – andar AB, UMIC, Av. Dr. Enéas de Carvalho Aguiar, 44, Cerqueira César, 05403-000 São Paulo, SP, Brazil, Phone: 55 11 3069-5376, FAX: 55 11 3069-5535, E-mail: bcaramel@usp.br
Received 11.21.2007 Revision Accepted 02.15.2008Atherosclerosis prevention in HIV
279
2 DO NOT COPY Kidney Function and the Risk of Cardiovascular Events in ...CID 2007 11 DO NOT COPY Urolithiasis in HIV Positive Patients Treated with...
program and cardiovascular risk reduction learned during phase II (37,39). ...t patients and increasingly focus on facilitating longterm behavior change (e...
Cardiovascular Risk Factors_临床医学_医药卫生_专业资料...a reduction in VAT has become a key therapeutic...patients.6,7 However, the association between VAT...
11 In HIV-positive patients with compensated liver...rate of reduction in CD4+ cell counts did not...Cardiovascular disease Cause of death Non-AIDS ...
therapy for HIV-infected patients has changed their prognosis substantially, but there is an additional cost from the increased risk of cardiovascular diseases...
stroke or cardiovascular death TW.RAM.09.01.01 MICRO-HOPE: Diabetic Patients (n = 3577) Risk Reduction (%) - All differences p<0.001 Combined endpoi...
J Hepatol 2003;38:257–65 Deaths in a cohort of 23,441 HIV patients on HAART HCV 35 30 25 20 15 10 5 0 AIDS Liver disease Cardiovascular disease...
(<50% patients with CVD) 二级 治疗方案 吉非贝齐 苯扎贝特 非诺贝特 单...Efficacy of fibrates for cardiovascular risk reduction in persons with ...
immunity may increase the risk that an influenza pandemic could occur," Dr...HIV-positive patients not receiving same consideration for cardiovascular disease...
Cardiovascular risk in i... 暂无评价 7页 免费 ...All patients were treated with the best ...risky behavior between HIV-positive individuals could...
热门文档